Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analyst sentiment is mixed: Seven brokerages give Century Therapeutics an average “Hold” rating, with four buys, two holds and one sell. The average 12-month price target is $4.75, above the reported trading price of $2.12.
• Recent ratings included an $8.00 price target and “outperform” rating from Mizuho, while HC Wainwright raised its target to $5.00 and maintained a buy rating; Weiss Ratings and Wall Street Zen issued sell assessments.
• Century reported quarterly EPS of -$0.11, beating the consensus estimate of -$0.15, but analysts expect a full-year loss of approximately $0.43 per share. Institutional investors own 50.20% of the company.

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has received an average recommendation of "Hold" from the seven brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $4.75.

Several brokerages have recently weighed in on IPSC. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. HC Wainwright raised their target price on shares of Century Therapeutics from $2.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday, April 21st. Mizuho assumed coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They set an "outperform" rating and a $8.00 price target on the stock. Finally, Wall Street Zen cut Century Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 27th.

Century Therapeutics Price Performance

IPSC traded up $0.10 during trading on Thursday, reaching $2.12. The company had a trading volume of 57,771 shares, compared to its average volume of 1,493,241. The company has a market cap of $383.24 million, a P/E ratio of -1.86 and a beta of 1.55. Century Therapeutics has a 12 month low of $0.44 and a 12 month high of $3.04. The business's fifty day moving average price is $2.25 and its 200 day moving average price is $2.23.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. As a group, sell-side analysts predict that Century Therapeutics will post -0.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its position in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock worth $67,000 after purchasing an additional 34,466 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock valued at $53,000 after buying an additional 86,875 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Century Therapeutics by 26.9% in the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company's stock valued at $86,000 after buying an additional 38,052 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Century Therapeutics by 101.2% during the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company's stock worth $133,000 after buying an additional 142,953 shares during the last quarter. Finally, Prudential Financial Inc. bought a new stake in Century Therapeutics during the second quarter worth $25,000. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.